Skip to content
Screener

Elanco Animal Health Inc. ELAN Business Segments — R&D

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — R&D
$17.19M+85.3%
Zscaler logo
ZSReportable Segment — R&D
$143.5M+35.4%
Snowflake logo
SNOWReportable Segment — R&D
$534.94M+13.2%
Veeva Systems logo
VEEVReportable Segment — R&D
$156.76M+15.2%
Bicara Therapeutics logo
BCAXReportable Segment — R&D
$47.5M+38.4%
Silicon Laboratories logo
SLABReportable Segment — R&D
$88.59M+0.4%

Other financials

Income statement

See full
Revenue$1.4B+10.2%
Gross profit$798.0M+11.9%
Net income$54.0M+391%
EPS (diluted)$0.11+450%

Balance sheet

See full
Cash & equivalents$530.0M-1.7%
Total debt$4.2B-6.2%
Total equity$6.6B-2.8%
Total assets$13.6B-1.3%

Cash flow

See full
Operating cash flow$277.0M+16.9%
CapEx$33.0M-42.1%
Free cash flow$244.0M+35.6%

Valuation

See full
Market cap$13.1B+89.0%
Enterprise value$16.81B+54.0%
P/S2.6×+1.1×

Profitability

See full
Gross margin55.4%+0.6pp
Net margin-4%-13.8pp
FCF margin7.5%-0.5pp

Returns & leverage

See full
Return on equity-3%-9.9pp
Debt / equity0.6×0.0×
Current ratio2.1×-0.5×

Where this comes from

Reported directly by Elanco Animal Health Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Elanco Animal Health Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001739104-26-000043
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue$1,368$1,241$2,739$2,434
Cost of sales5705281,1561,037
Gross profit7987131,5831,397
Research and development9292189186
Marketing, selling and administrative449400830741
Amortization of intangible assets139136277264
Asset impairment, restructuring and other special charges912510
Interest expense, net of capitalized interest594811688

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Elanco Animal Health Inc.'s business segments — R&D?
Elanco Animal Health Inc. (ELAN) reported business segments — R&D of $92M in Q2 2026.
How has Elanco Animal Health Inc.'s business segments — R&D changed year-over-year?
Elanco Animal Health Inc.'s business segments — R&D decreased by 0.0% year-over-year, from $92M to $92M.
What is the long-term trend for Elanco Animal Health Inc.'s business segments — R&D?
Over 3 years (2022 to 2025), Elanco Animal Health Inc.'s business segments — R&D has grown at a 4.7% compound annual growth rate (CAGR), from $321M to $368M.
What does business segments — R&D mean?
Represents expenditures dedicated to the discovery, innovation, and clinical development of new animal health products. This is a critical investment for maintaining a competitive pipeline and long-term growth.

Ask your AI about Elanco Animal Health Inc.'s business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude